NEW YORK, May 3, 2017 /PRNewswire/ -- Digipath, Inc. (DIGP), an independent cannabis lab testing and media firm, is pleased to announce it has appointed John Abroon, M.D. as the initial member of its Advisory Board.
Dr. Abroon is a board-certified general practitioner who specializes in diagnostic and preventative medicine, completing his residency program at Westchester County Medical Center in 1986. He completed three years of research in liver diseases, and has published a number of articles on liver cirrhosis in The American Journal of Gastroenterology and the Journal of Hepatology.
Dr. Abroon is affiliated with Mount Sinai and Lenox Hill hospitals and has strong working relationships with prestigious New York specialists at a number of area hospitals and medical facilities. Dr. Abroon has an interest in preventative medicine and wellness care, and he incorporates alternative therapies into cutting-edge medical practices.
Joseph Bianco, the CEO of Digipath, commented, "As the legalization of medicinal marijuana spreads throughout the U.S., it's important for Digipath to maintain and build its relationship with the medical community and especially those practitioners that are seeking alternative therapies. Adding Dr. Abroon to Digipath's Advisory Board is an important step in this process."
About Digipath, Inc.
Digipath, Inc. is an independent cannabis testing and media firm that supports the cannabis industry's best practices for reliable testing and delivers cannabis news coverage and education about the cannabis industry. Digipath's two business units are Digipath Labs and TNM News Corp. Digipath Labs™ is working to set the industry standard for testing all forms of cannabis-based products using FDA-compliant laboratory equipment and proprietary standard operating procedures (SOP) to ensure product safety and efficacy. TNM News Corp. has pioneered a cannabis-focused news network, The National Marijuana News, which delivers news, interviews, and education on all things cannabis.
For more information please visit http://www.Digipath.com/
This press release contains "forward-looking statements" that include information relating to future events, and future financial and operating performance. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, governmental regulation of the cannabis industry, the demand for the Company's products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Viridian Capital Advisors, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/digipath-appoints-dr-john-abroon-to-advisory-board-300450345.html